Andrew is the founder, CEO and MD of BioPharmaSpec and has 25 years’ experience in the analysis of both novel and biosimilar biopharmaceuticals.
In this interview, Andrew explains why mass spectrometry is such a powerful tool for developers in understanding the structure of their target biopharmaceutical, and how they can get the most informative data by using appropriate analytical strategies at the right time.
